

The Pharma Legal Handbook

China

Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical
Trial Requirements · Marketing, Manufacturing, Packaging and Labeling
Advertising · Traditional Medicines and OTC Products · Product Liability ·
Patents and Trademarks · Regulatory Reforms

China

The Pharma Legal Handbook answers essential questions about this environment for pharmaceuticals in China. It is a must have for any company operating in the country or looking to enter the market.

Prepared in association with Fangda Partners, a leading chinese law firm, it should answer any questions linked to Regulation, Pricing, Clinical and Preclinical Trials, Marketing, Manufacturing, Trademarks and Patents.

PharmaBoardroom is not responsible for any mistakes contained within this publication. For specific advice on any legal issue, please contact a qualified professional.

Copyright: All rights reserved. No part of this publication may be reproduced in any form or by any means, whether electronic, mechanical or otherwise including photocopying, recording or any information storage or retrieval system without prior written consent of PharmaBoardroom. While every attempt is made to ensure the accuracy of the information contained in this report, neither Focus Reports nor the authors accept any liabilities for errors and omissions. Opinions expressed in this report are not necessarily those of the authors.

*** THIS REPORT WAS ORIGINALLY PUBLISHED IN DECEMBER 2018 AND THE INFORMATION CONTAINED WITHIN IS SUBJECT TO CHANGE.**

FANGDA PARTNERS 方達律師事務所

Fangda Partners is one of the first private PRC law firms established under China's contemporary legal system. We have over 550 lawyers serving international and domestic clients in various commercial matters through our teams in Beijing, Guangzhou, Shanghai, Shenzhen and Hong Kong. We are one of the leading full service PRC and Hong Kong commercial law firms with practices covering general corporate, merger and acquisition, private equity, capital markets, intellectual property, real estate, construction, infrastructure development, dispute resolution, banking and finance, labour and employment, dispute resolution and other important areas of legal practices.

We pride ourselves on the quality of our work. Our goal is to be the firm of choice for the most challenging transactions and most difficult legal issues in China. The two characters of the firm's Chinese name, "fang" and "da", meaning "integrity" and "open-mindedness", are a short-form mission statement of our practice.

THE AUTHORS



**JOSH
SHIN**

PARTNER

Mr. Josh Shin specializes in M&A, general corporate advices, private equity investment, and overseas capital markets, with a strong track record in various legal issues in the pharmaceutical, life science and healthcare sectors.

Mr. Shin leads the healthcare practice of the firm's corporate group. His experience in the sector includes major transactions in the sub-areas of pharmaceuticals, medical devices and medical services, as well as regularly offering advice to clients on regulatory developments in issues at the forefront of this area of law. Josh's recent experience in the healthcare area includes proposed acquisition by private equity fund of Cardinal Health's China business, Bayer's acquisition of Dihon Pharmaceuticals, Wuxi AppTec's joint venture with Mayo Clinics, exclusive commercialization/licensing arrangement of a number of drugs owned by big pharma, and the overseas IPO of a number of biotech companies. Mr. Shin is nominated as recognized practitioner for Healthcare by Chambers Asia Pacific 2019.



**TIANSHAN
WANG**

ASSOCIATE

Mr. Tianshan Wang is a corporate lawyer based in the Shanghai office of Fangda Partners. He has extensive experience over healthcare related matters, including: representing BeiGene in its secondary offering on the main board of Hong Kong Stock Exchange; representing J.P. Morgan in the initial public offering and listing of Zai Lab on NASDAQ; representing Novartis and AstraZeneca in its granting of exclusive commercialization rights to other pharmaceutical companies; and advising multi-national pharmaceutical corporations including Bayer, AstraZeneca, Mylan, Carestream Dental on their general corporate matters such as FDI, liquidation, merger and division, compliance, sales and distribution. Tianshan Wang is qualified to practice in the PRC.

SIMPLY EXCELLENT



Founded in 1993, we are one of the first private partnership law offices in China



Our outstanding team consists of 108 partners and 485 lawyers



We have offices in Beijing, Shanghai, Shenzhen, Guangzhou and Hong Kong



Our recognitions by Chambers, one of the most authoritative legal ranking publications in the world

Ranked band **1** in 10 practicing areas with **44** individuals mentioned in 15 practicing areas



As one of the most respected law firms in China, we receive our awards and accolades from various institutions

Top Tier Firm (China)
IFLR 1000 Financial Law Firm Rankings (2019)

China Firm of the Year
China Law and Practice (2018)

Technology, Media & Telecom M&A
Legal Adviser of the Year
Mergermarket 2018 China M&A Awards

M&A Firm of the Year – China
China Law and Practice (2018)

Competition Firm of the Year – China
China Law and Practice (2018)

Corporate Investigations/
Anti-Corruption (PRC Firms) - China
Chambers Asia-Pacific 2018

China Domestic Patent Law Firm (Tier 1)
Asian Legal Business 2018

China PRC Law Firm of the Year –
Dispute Resolution
Chambers Asia Pacific (2018)



We are undisputable leaders in almost all of our focused areas:

- ★ M&A
- ★ Private Equity
- ★ Dispute Resolution
- ★ Bankruptcy and Reorganization

- ★ Healthcare
- ★ Anti-trust and Competition Law
- ★ IP litigation
- ★ Regulatory compliance

CONTENTS

01 REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW

Page 6

02 PRECLINICAL AND CLINICAL TRIAL REQUIREMENTS

Page 16

03 MARKETING, MANUFACTURING, PACKAGING AND LABELING ADVERTISING

Page 20

04 TRADITIONAL MEDICINES AND OVER-THE-COUNTER PRODUCTS

Page 29

05 PRODUCT LIABILITY

Page 33

06 PATENTS AND TRADEMARKS

Page 38

07 REGULATORY REFORMS

Page 45

01

REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW

1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country?

2. What is the regulatory framework for the authorization, pricing, and reimbursement of drugs, biologicals, and medical devices?

3. What are the steps to obtaining authorization to develop, test, and market a product?

4. What are the approximate fees for each authorization?

5. For how long are marketing authorizations/registrations valid? How are marketing authorizations/registrations renewed?

6. How does the authorization process differ between brand-name products and generic products? Are there differences for local manufacturers versus foreign-owned manufacturers?

7. How are combination products (drug + drug, drug + biologic, drug + device, biologic + device, drug + biologic + device) regulated?

8. How is compliance with regulation monitored and evaluated? Is the regulatory regime comparable with the U.S. Food and Drug Administration or the European Medicines Agency expectations and requirements?

9. What is the potential range of penalties for noncompliance?

10. Is there a national healthcare system? If so, how is it administered and funded?

11. How does the government (or public) healthcare system function with private sector healthcare?

12. Are prices of drugs and devices regulated and, if so, how?

13. How are drugs and devices used by patients paid for? What roles do public and private payers play?

14. Who dispenses drugs and devices to patients and how are those dispensers compensated?

15. What are the professional and legal responsibilities of those who dispense drugs and devices? What role do they play in providing patient care, information, and safety?

01 REGULATORY, PRICING, AND REIMBURSEMENT OVERVIEW

1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country?

Responsibilities for the administration of drugs (including biologicals) and medical devices are assumed by several governmental agencies, including the following key players:

- National Medical Product Administration (NMPA), formerly known as China Food and Drug Administration, which is responsible for issuing marketing authorizations of drugs and medical devices and monitoring product quality.
- National Health Commission (NHC), which is responsible for the overall guidance of healthcare reform, administering China's Essential Drug List (EDL) and managing the drug tendering and procurement policies.
- Ministry of Human Resources and Social Security (MOHRSS), the authority that takes the lead in formulating the National Drug Reimbursement List (NRDL).

2. What is the regulatory framework for the authorization, pricing, and reimbursement of drugs, biologicals, and medical devices?

DRUGS

Key Regulations

The fundamental legislations for the drug industry are the Drug Administration Law and its Implementing Rules. A wide range of other regulations and implementing measures have been issued by the NMPA to guide the pharmaceutical industry.

Authorization

Steps to obtain the marketing authorization for drugs are mainly set out in the Drug Registration Administrative Measures. In general, all new drugs must go through four steps before being marketed: pre-clinical research, application for clinical trial, clinical trial and approval for production.

- Pre-clinical research of a drug shall be conducted in accordance with the Good Laboratory Practices (GLP).
- After completing the pre-clinical research, the applicant must obtain approval for clinical trials from the NMPA's Center for Drug Evaluation (CDE) to conduct new clinical drug trials. In July 2018, NMPA promulgated a new rule that if an applicant for clinical trial does not receive any negative opinions from the CDE within 60 days after the date of accepting the application, the drug clinical trials may be conducted in accordance with the plan submitted to the CDE.
- After the approval of a clinical trial, the applicant shall conduct the clinical trial at good-clinical-practice (GCP) certified institutions. Clinical

trials are divided into Phase I, Phase II, Phase III and Phase IV, among which, Phase IV is post-marketing clinical trials.

- Upon completion of Phase III clinical trial, the applicant can submit a new drug application for approval to manufacture and launch such new drugs.

Pricing

The price control of drugs was previously based upon a scheme of maximum retail price (MRP) of drugs set by the government, which was abolished (with the exception of narcotic and certain psychotropic drugs) in June 2015. On the other hand, public hospitals were allowed to mark-up drugs by around 15% above procurement prices, which has been replaced by the “zero-mark-up” (i.e., no-profit, the drug price that hospital charges the patient should be the same as it pays to the drug suppliers) policy since July 2017.

Reimbursement

In terms of the reimbursement of drugs, China’s medical insurance system was first adopted in 1998 and has now been gradually expanded to provide coverage for the majority of the population. Participants of the national medical insurance program and their employers (if any), are required to contribute to the payment of an insurance premium on a monthly basis. Medical insurance program participants are eligible for full or partial reimbursement of the cost of medicines included in the NRDL, which includes 2,535 drugs that are divided into Class A and Class B drugs. Class A drugs typically include low-priced and clinically necessary drugs that are fully reimbursed, and the Class B drugs catalogue typically includes higher-priced or new drugs that generally require the patients to assume 10-30% of the drug’s cost. Each province is allowed to issue its own drug reimbursement list (PRDL) based upon the NRDL, provided that Class A drugs in the NRDL should be kept and maintained and the adjustment to the Class B drugs should not be greater than 15%.

MEDICAL DEVICES

Key Regulations

The fundamental legislation for the medical device industry is the Medical Device Supervision and Administration Regulations. A wide range of other regulations and implementing measures have been issued by the NMPA to guide the medical device industry.

Authorization

Under the Medical Device Registration Administrative Measures, devices can be categorized into Class I, Class II and Class III devices. Class I devices are simple devices that are exempted from clinical trials and administered through a filing system. Class II and Class III devices are more complex devices with medium or high risks and should be supported by clinical trials (unless being on the list of devices exempted from clinical trials) and registered with the NMPA before entering into the market.

Pricing

There is no MRP scheme in the medical device sector. Similar to the mark-up policy previously applicable to drugs, public hospitals are still allowed to charge a certain mark-up on the medical devices purchased by them (for example, a maximum of 5% mark-up is allowed in Shanghai, provided that the purchase price for a medical device exceeds RMB 4,000, and the mark-up should not exceed RMB 200).

Reimbursement

At the national level, there is a negative list that precludes certain devices (such as glasses and massage devices) from governmental reimbursement. Detailed reimbursement coverage and rate for medical devices are subject to local policies at each province.

3. What are the steps to obtaining authorization to develop, test, and market a product?

Please refer to [Question 2 of Chapter 1](#) regarding the authorizations of drugs and medical products.

4. What are the approximate fees for each authorization?

The table below lists the government fees charged by NMPA for each category of registration:

CATEGORY	SUB-CATEGORY		FEE (RMB 10,000)
Domestic drug	New drug	Clinical trial approval	19.2
		Marketing authorization	43.2
	Generic drug	Marketing authorization (clinical trial is waived)	18.36
		Marketing authorization (clinical trial is required)	31.8
	Supplementary registration	Regular registration items	0.96
		Registration items requiring technical review	9.96
	Renewal application		Set by the provincial authority
Imported drugs	New drug	Clinical trial approval	37.6
		Marketing authorization	59.39
	Generic drug	Marketing authorization (clinical trial is waived)	36.76
		Marketing authorization (clinical trial is required)	50.2
	Supplementary registration	Regular registration items	0.96
		Registration items requiring technical review	28.36
	Renewal application		22.72